Grommes, Christian <br/><br/>
Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.  [electronic resource] 

 -  Blood  01 2019 
 - 436-445 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2018-09-875732  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenine--analogs & derivatives<br/>Adult<br/>Agammaglobulinaemia Tyrosine Kinase--antagonists & inhibitors<br/>Aged<br/>Antineoplastic Agents--adverse effects<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Central Nervous System Neoplasms--drug therapy<br/>Circulating Tumor DNA--genetics<br/>Female<br/>Humans<br/>Lymphoma--drug therapy<br/>Methotrexate--adverse effects<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Piperidines<br/>Protein Kinase Inhibitors--adverse effects<br/>Pyrazoles--adverse effects<br/>Pyrimidines--adverse effects<br/>Rituximab--adverse effects<br/>Treatment Outcome<br/>Young Adult